Agoracom Blog Home

Posts Tagged ‘tsx’

Kiaro, One Of Canada’s Largest Cannabis Retailers, To Leverage The Power Of Fobi Real-time Artificial Intelligence To Transform Their Approach To Cannabis Retail

Posted by AGORACOM-JC at 5:46 PM on Wednesday, September 29th, 2021
Kiaro holdings corp  kiaro completes kelowna cannabis retail loc

“I was blown away by FOBI “  ($KO CEO Daniel Petrov)

“Kiaro has built an amazing tech driven cannabis retail business”  ($FOBI CEO Rob Anson)

If you’re a shareholder of one of these companies, here is what you need to know about each that makes this technology partnership so powerful:

KIARO is one of Canada’s largest retailers of cannabis, with 16 locations and forecasted annual revenue of $42.7 million from these locations, at a gross profit of $13.7M with further growth anticipated.

FOBI is a global leader in providing real-time data analytics through artificial intelligence to drive customer activation and engagement in the brick and mortar space.  From that core technology they have built a technology stack on top of it that is second to none.

More than just talk, FOBI has completes Integrations with Lightspeed and Shopify to provide real-time Point of Sale data analytics.  Moreover, they recently announced another $250.000 Data Consulting Agreement with Azincourt Energy

TOGETHER they combined forces in this press release “Fobi Signs $240,000 Data Consulting Agreement With Kiaro Holdings, A National Cannabis Retailer With 16 Locations And Forecasted Annual Revenue Of $42.7 Million, To Assist With Development Of Data Warehouse”

How important is this agreement to each other’s success? 

Very. 

Watch this powerful interview with FOBI CEO, Rob Anson and Kiaro CEO Daniel Petrov to find out exactly.

VIDEO – With $17M In Profitable Cannabis Revenues Already, The Latest Kiaro Acquisitions Are Expected To Create $43M In Revenue & $13.7M Gross Profit

Posted by AGORACOM-JC at 4:54 PM on Friday, July 16th, 2021
Kiaro holdings corp  kiaro completes kelowna cannabis retail loc

Kiaro Holdings is an multi-channel cannabis retailer and distributor with existing storefronts across British Columbia , Saskatchewan and Ontario, a wholesale distribution servicing Saskatchewan and ecommerce sites in Canada , the US and Australia, which have resulted in the following:

  • ANNUAL REVENUE              $17.1M Up 230%
  • ANNUAL GROSS PROFIT     $5.1M Up 281%  
  • Q1 REVENUE                          $5.2M Up 94%
  • Q1 GROSS PROFIT                 $1.56M Up 118%

But CEO Daniel Petrov and his team of retail winners aren’t stopping there. On July 13th, $KO announced  Kiaro Acquires Hemisphere Cannabis and Adds 7 Retail and 2 Development Locations in Ontario To Become a Prominent National Cannabis Retailer with Forecasted Annual Revenues of $42.7 Million.

If you believe in the long-term future of the cannabis market, then you have to discover KIARO by watching our first ever interview with CEO Daniel Petrov.

VIDEO – Universal PropTech (UPI: TSXV) (UPIPF: OTCQB) Talks Growing Backlog At ~ $6 Million, Organic Growth, Tier-1 Customers and More

Posted by AGORACOM-JC at 4:06 PM on Monday, July 12th, 2021
This image has an empty alt attribute; its file name is SMS-Smalljpg-1.jpg

As the name implies “PropTech” is a combination of two words and stands for “property technology.”  As simple as that is, the implementation and importance of PropTech is anything but, which is why many companies are trying to capitalize on the rapidly growing paradigm shift, while Universal PropTech (UPI:TSXV) is actually delivering healthy building solutions developers, owners and operators across Canada. 

More than just lip service, UPI clients include:

· Federal Government facilities for over 40 years 

· Manulife 

· Brookfield 

· Billy Bishop Airport 

· University of Toronto 

· …. and many more 

The company’s backlog is now a staggering $~6 million.

This represents:

  • + $800,000 from April
  • + $3,000,000 swing from September

This is comprised of awarded and not executed work, made up of a combination of service contracts and project work in both HVAC Building Automation and Mechanical lines of business.

We sat down with Frank Carnevale, CGO of Universal Proptech, to talk about their multimillion-dollar backlog. Check out the full interview below.

Awakn Life Sciences to Commence Trading on the NEO Exchange Under the Symbol $AWKN

Posted by AGORACOM-JC at 12:18 PM on Wednesday, June 23rd, 2021
  • Strategic focus on developing and delivering psychedelic medicines to treat Addiction.
  • Strong psychedelic drug development pipeline targeting Addiction.
  • First mover advantage for clinics in the UK and the EU with 400m people and CAD$25TR GDP.
  • The leading research and clinical team in the industry focused on using psychedelics to treat Addiction.
  • Multiple scalable revenue streams across drug development and clinical delivery.

Toronto, Ontario–(June 23, 2021) – Awakn Life Sciences Corp. (NEO: AWKN) (“Awakn” or the “Company“) a biotechnology company with clinical operations developing, and delivering psychedelic medicines to treat Addiction, is pleased to announce it will begin trading today, June 23, 2021, on the NEO Exchange Inc. (the “NEO”) under the symbol “AWKN”.

“Listing on the NEO is an important milestone for Awakn to continue to build on our dual strategic focus of developing psychedelic drugs, therapies, and enabling technologies to treat Addiction, and delivering psychedelic treatments for Addiction in our clinics,” said Awakn CEO, Anthony Tennyson. “The NEO listing will enable us to accelerate the execution of our drug discovery, therapy development, advanced analytics, and open clinic roll out programs.”

The listing follows the successful completion of the previously announced reverse takeover of a Canadian public company, 2835517 Ontario Ltd., by Toronto-based Awakn Life Sciences Inc. The public company was subsequently renamed Awakn Life Sciences Corp. in connection with the reverse takeover and the listing on the NEO. Additionally, the Company raised gross proceeds of approximately USD$8.3 million through a brokered private placement.

Awakn engaged Canaccord Genuity Corp. and Eight Capital as co-lead agent and joint bookrunners to complete the brokered financing. In connection with the transaction, 2835517 Ontario Ltd. was de-listed from the NEX board of the TSX Venture Exchange.

A filing statement with information about Awakn prepared in accordance with the policies of the NEO is available on SEDAR at www.sedar.com.

About Awakn Life Sciences

Awakn Life Sciences is a biotechnology company with clinical operations, researching, developing, and delivering psychedelic medicine to better treat Addiction. Awakn’s team consists of world leading chemists, scientists, psychiatrists, and psychologists who are developing and advancing the next generation of psychedelic drugs, therapies, and enabling technologies to treat Addiction. Awakn will also deliver evidence backed psychedelic therapies for Addiction in clinics in the UK and Europe and through licencing partnerships globally.

www.awaknlifesciences.com | Twitter | LinkedIn | Facebook

Forward Looking Statements

This news release contains certain forward-looking information and forward-looking statements, as defined in applicable securities laws (collectively referred to herein as “forward-looking statements”). Forward-looking statements reflect current expectations or beliefs regarding future events or the Company’s future performance. All statements other than statements of historical fact are forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “continues”, “forecasts”, “projects”, “predicts”, “intends”, “anticipates”, “targets” or “believes”, or variations of, or the negatives of, such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “should”, “might” or “will” be taken, occur or be achieved, including statements relating to the proposed NEO listing, and the business of the Company. All forward-looking statements, including those herein are qualified by this cautionary statement.

Although the Company believes that the expectations expressed in such statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the statements. There are certain factors that could cause actual results to differ materially from those in the forward-looking information. These include: whether conditions to the listing on NEO will be satisfied; the business plans and strategies of the Company, the ability of the Company to comply with all applicable governmental regulations in a highly regulated business; the inherent risks in investing in target companies or projects which have limited or no operating history and are engaged in activities currently considered illegal in some jurisdictions; changes in laws; limited operating history; reliance on management; requirements for additional financing; competition; inconsistent public opinion and perception regarding the medical-use of psychedelic drugs; and regulatory or political change. Readers are cautioned that the foregoing list of factors is not exhaustive of the factors that may affect forward-looking statements. Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release speak only as of the date of this news release or as of the date or dates specified in such statements.

Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking information. For more information on the Company, investors are encouraged to review the Company’s public filings on SEDAR at www.sedar.com. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.

This news release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States. The Company’s and Awakn’s securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Investor Enquiries:
KCSA Strategic Communications
Valter Pinto / Tim Regan
Phone: +1 (212) 896-1254
[email protected]

Media Enquiries:
America and Canada: KCSA Strategic Communications
Anne Donohoe
[email protected]

Rest of World: ROAD Communications
Paul Jarman / Anna Ramsey
[email protected]

VIDEO – Awakn Life Sciences Corp. $AWKN Is Addressing The Multi-Billion Dollar #Addiction Treatment Industry With #Psychedelics

Posted by AGORACOM-JC at 12:14 PM on Wednesday, June 23rd, 2021

To understand Awakn you first have to understand that …. Psychedelics are going to go through a parabolic, paradigm shifting growth in the next 5 years because of their ability to treat anxiety, depression and addiction … amongst other things Awakn Life Sciences is a biotechnology company with clinical operations developing, and delivering psychedelic medicine to better treat Addiction.  

Awakn has a dual strategic focus: 

  1. Development: Research & developing the next generation of psychedelic drugs, therapies, and enabling technologies to better treat Addiction.
  2. Delivery: Awakn will deliver evidence backed psychedelic therapies for Addiction in clinics in the UK and Europe and through licensing partnerships globally. 

Notable Highlights include: 

  • Strategic focus on better treating Addiction with psychedelics.
  • World leading team focused on psychedelic drug and therapy research. 
  • Strong drug and therapy development pipeline, specifically targeting Addiction.
  • Clinics, which will be the UK and EU’s leading medical psychedelic therapy delivery 
  • Closed $8.3M June 8
  • BRAND NEW LISTING … commencing trading on NEO

Sit back, relax and watch this powerful interview with CEO Anthony Tennyson. 

VIDEO – POET Technologies $PTK.ca $POETF Describes OFC Conference as an “Inflection Point”

Posted by AGORACOM-JC at 4:47 PM on Monday, June 14th, 2021

POET Technologies (PTK: TSXV) (POETF: OTCQX) Vivek Rajgarhia, Thomas Mika and I discuss the success of their demos at the  2021 Optical Fiber Communication Conference and Exhibition (OFC) .

POET hosted a Gold-level sponsored booth showcasing the company’s latest news, products and video demonstrations.

Vivek describes the conference as an “inflection point” … and the smiles on their faces are hard to ignore! 

Sit back and watch this powerful interview!

Fabled Silver Gold $FCO $FBSGF Spins Out 20+ Copper Occurrences & 3 Classified Deposits Into Fabled Copper Co. $CMMC $NDM $CS $GMBXF

Posted by AGORACOM-Eric at 5:02 PM on Wednesday, May 19th, 2021
This image has an empty alt attribute; its file name is fabled-square.png

VIDEO – PyroGenesis $PYR Now Delivering 3D Printing Powders That “Top Global Aerospace Companies Have Been Waiting For” $MTLS $DDD $SSYS

Posted by AGORACOM-JC at 7:22 PM on Wednesday, May 12th, 2021

PyroGenesis is the world leader in the design, development, manufacture and commercialization of advanced plasma processes and products.  In short, their plasma torch technology has been the foundation of multiple successful applications around the world.

One of those applications is ultra high-tech 3D printing powders that earned the company multiple nominations for “Materials Company of the Year” at the 3D Printing Industry Awards as recently as 2019.

Today, PyroGenesis announced “Successful Completion of Additive Manufacturing NexGen™ Powder Test Runs; Commercial Powder Production Begins”

HOW BIG IS THIS? 

These 2 quotes tell you everything you need to know  

“It is very exciting to know that we are now going to be delivering powders to very discerning and distinguished clients.

With the advantages of the NexGen™ powder production line, we believe it is only a matter of time given the major top tier aerospace companies and OEMs are already awaiting powders from this new state-of-the-art production line.”

“The next step is to complete the qualification processes and secure large long-term contracts, thereby providing PyroGenesis with recurring revenues for years to come.”

Watch our great interview with CEO Peter Pascali .

VIDEO – $HPQ.ca Silicon Production Milestone Moves Company Closer To Awaiting Battery Manufacturers and Automobile Manufacturers HPQFF $ENPH $BE $NNO $PYR

Posted by AGORACOM-JC at 4:42 PM on Friday, April 23rd, 2021

HPQ Silicon Resources $HPQ $HPQFF is a Quebec-based company that is developing a portfolio of high value-added silicon products sought after by battery and electric vehicle manufacturers.  

If that sounds a lot like what other small companies are saying lately, $HPQ differentiates itself as a leader of the pack thanks to the following: 

Yesterday, the Company announced a major milestone with this press release HPQ Gen1 Nano Silicon Reactor Exceeds Phase 1 Production Rate Target By 67%

To discuss the importance and the implications of this milestone, this excerpt from the press release says it all:

“Once the final equipment modifications are completed, the goal of the program will be to produce qualified samples which will then be tested by a third-party, the Institut National de Recherche Scientifique (INRS), and subsequently to awaiting battery manufacturers and automobile manufacturers.”

 Peter Pascali, President and CEO of PyroGenesis added a little more excitement when he stated

“It is even more exciting when one considers the impact this could have on addressing the challenges facing the EV battery space.”

Watch this great interview with $HPQ CEO Bernard Tourillon to get the full picture on next steps!

VIDEO – Cardiol Therapeutics $CRDL.ca $CRTPF is a Clinical-Stage Biotech Firm taking on the $30BN Heart Disease Healthcare Market via Cannabidiols and Cutting-Edge Anti-Inflammatory Therapies

Posted by AGORACOM-JC at 4:23 PM on Thursday, April 22nd, 2021

Cardiol Therapeutics $CRDL.ca $CRTPF is a groundbreaking, clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease (heart/blood vessels).

  • The company has received approval from the U.S. FDA to commence a Phase II/III, double-blind, placebo-controlled clinical trial investigating the efficacy and safety of its lead clinical product, CardiolRx™, in treating hospitalized COVID-19 patients with a prior history of, or risk factors for, cardiovascular disease (CVD).
  • CardiolRx™ is an ultra-pure, high concentration cannabidiol oral formulation that is pharmaceutically produced, manufactured under cGMP and THC free.

Cardiol is also planning a Phase II international trial of CardiolRx™ in acute myocarditis, a condition caused by inflammation in heart tissue, most common cause of sudden cardiac death in people under 35.

The company is also developing proprietary cannabidiol formulations for the treatment of chronic heart failure.

One such key development is its commercial product, Cortalex™, an extra-strength formulation (100 mg/mL concentration) of cannabidiol oil that is pharmaceutically produced to be free of THC. Cardiol believes Cortalex™ to be the purest form of cannabidiol oil available in Canada.

It is the first THC-free extra-strength formulation of cannabidiol oil available across Canada exclusively online at Medical Cannabis by Canada’s largest pharmacy retailer, Shoppers Drugs Mart.

  • In March 2020, Cardiol signed a supplier agreement to become a medical cannabidiol supplier to Shoppers Drug Mart. The retailer will supply Cardiol’s pharmaceutical cannabidiol products to Shoppers for sale in all provinces and territories in Canada through Shoppers’ online store, Medical Cannabis by Shoppers.

And there’s plenty more to write home about:

  • ~ $27M from exercise of warrants + equity raise since June 2020
  • Uplisting to NASDAQ
  • Team expansion with Chief Medical Officer hire

David Elsley, Cardiol Therapeutics’ President & CEO, gives us the low-down. Check it out: